Oaktree Acquisition Corp. III Life Sciences (OACC) · Oct 15, 2026 · Other events
13.3M shares redeemed — 13,326,977 shares tendered for redemption
Oaktree Acquisition III reports 13.3 million share redemptions before its October 16 extension vote, leaving a much smaller public base.
Oaktree Acquisition Corp. III Life Sciences is a healthcare-focused SPAC running out of time to complete a business combination; it is asking shareholders to extend the deadline from October 25, 2026, to November 25, 2026, with possible monthly extensions through May 25, 2027.
The extension effort comes with a severe reduction in the public shareholder base. Shareholders tendered 13,326,977 Class A shares for redemption before the deadline. 〔0〕 After the sponsor’s converted shares are excluded, the filing implies only about 5.9 million public shares would remain, meaning roughly two-thirds of the pre-redemption public base is leaving.
The sponsor’s share conversion preserves voting control but does not replenish public capital. Oaktree Acquisition Holdings plans to convert 4,798,758 Class B founder shares into Class A shares, all still subject to founder restrictions and ineligible for redemption. 〔1〕 The conversion does not increase the sponsor’s voting power because both share classes vote together. 〔2〕
This keeps the SPAC alive, but leaves the eventual transaction with a thinner shareholder and funding base. Assuming the redemptions and conversion occur, OAC expects 11,254,791 Class A shares and 1,000 Class B shares outstanding. The direction was already telegraphed by the extension solicitation; the new information is the magnitude of shareholder withdrawals rather than the existence of the extension process.
Bottom line: OACC has preserved a path to keep searching for a deal, but the heavy redemptions materially weaken its public-capital base. The October 16 vote is the immediate test, while the larger business question—whether the remaining structure can still produce an attractive combination—remains unresolved.
October 16 extension vote
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!